See more : Shaftesbury PLC (SHABF) Income Statement Analysis – Financial Results
Complete financial analysis of Chemomab Therapeutics Ltd. (CMMB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chemomab Therapeutics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Axiata Group Berhad (6888.KL) Income Statement Analysis – Financial Results
- Federal National Mortgage Association (FNMAT) Income Statement Analysis – Financial Results
- Tencent Holdings Limited (NNND.F) Income Statement Analysis – Financial Results
- Alumina Limited (AWCMF) Income Statement Analysis – Financial Results
- Annabidiol Corp. (ACBD) Income Statement Analysis – Financial Results
Chemomab Therapeutics Ltd. (CMMB)
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2012 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 66.83K | 57.77K | 34.02K | 80.00K | 281.91K | 66.00K | 51.00K | 40.64K | 26.25K | 0.00 |
Gross Profit | -66.83K | -57.77K | -34.02K | -80.00K | -281.91K | -66.00K | -51.00K | -40.64K | -26.25K | 0.00 |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 18.38M | 16.98M | 6.33M | 4.68M | 13.35M | 7.51M | 6.23M | 2.34M | 5.96M | 15.72M |
General & Administrative | 7.08M | 11.56M | 6.03M | 1.29M | 960.00K | 374.00K | 0.00 | 0.00 | 0.00 | 5.65M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 5.96M | 5.08M | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 7.08M | 11.56M | 6.03M | 1.29M | 5.98M | 5.46M | 3.11M | 2.25M | 1.14M | 5.65M |
Other Expenses | 0.00 | 0.00 | 0.00 | 749.00K | 3.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 25.46M | 28.53M | 12.37M | 5.97M | 19.33M | 12.97M | 9.34M | 4.59M | 7.11M | 21.37M |
Cost & Expenses | 25.46M | 28.53M | 12.37M | 5.97M | 19.61M | 13.04M | 9.39M | 4.63M | 7.13M | 21.37M |
Interest Income | 1.23M | 351.62K | 65.00 | 20.00K | 393.00K | 0.00 | 1.00K | 521.00 | 1.03K | 0.00 |
Interest Expense | 0.00 | 353.00K | 111.08K | 6.00K | 9.00K | 0.00 | 5.00K | 0.00 | 14.16K | 0.00 |
Depreciation & Amortization | 67.00K | 57.77K | 34.02K | 80.00K | 281.91K | 66.00K | 51.00K | 40.64K | 26.25K | 0.00 |
EBITDA | -25.39M | -28.48M | -12.33M | -5.95M | -26.92M | -13.36M | -9.50M | -4.57M | -7.46M | 24.18M |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -25.46M | -28.53M | -12.40M | -5.97M | -19.61M | -13.04M | -9.39M | -4.63M | -7.13M | 24.18M |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 1.24M | 353.00K | -111.00K | 21.00K | -7.60M | -455.52K | -164.63K | 20.69K | -367.79K | 29.24M |
Income Before Tax | -24.22M | -28.18M | -12.48M | -5.95M | -27.21M | -13.49M | -9.48M | -4.60M | -7.50M | 24.18M |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | -534.00K | 77.00K | -21.00K | 1.00 | 306.00K | 323.00K | 136.24K | -3.00 | 0.00 |
Net Income | -24.22M | -27.65M | -12.56M | -5.93M | -27.21M | -13.80M | -9.81M | -4.73M | -7.50M | 24.18M |
Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -2.06 | -2.43 | -1.21 | -3.20 | -15.80 | -21.84 | -217.31 | -17.42 | -32.94 | 0.00 |
EPS Diluted | -2.06 | -2.43 | -1.21 | -3.20 | -15.80 | -21.84 | -217.31 | -17.42 | -32.94 | 0.00 |
Weighted Avg Shares Out | 11.75M | 11.38M | 10.37M | 1.85M | 1.72M | 631.70K | 45.13K | 271.67K | 227.69K | 50.11B |
Weighted Avg Shares Out (Dil) | 11.75M | 11.38M | 10.37M | 1.85M | 1.72M | 631.70K | 45.13K | 271.67K | 227.69K | 50.11B |
Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
Chemomab Therapeutics Announces $10 Million Private Placement
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know
Source: https://incomestatements.info
Category: Stock Reports